• Low spreads and over 20 instruments at your disposal
• Low commission from 1.2 per transaction (0.1 lot)
• Low fixed spreads
• Possibility to trade in mini lots
• Instant Execution Technology: Trade transactions are conducted instantaneously at real-time streaming prices without the need to request prices from your broker
• Guaranteed execution of limit orders, S/L (stop loss) orders and T/P (take profit) orders at stated prices
• Minimum lot of 10,000 units (0.1 lot)
• Minimum initial deposit of 300 US dollars or equivalent
• Absence of swap points.

  Due to an excellent service:

• The trade desk is available for trade transactions via the Internet and over the telephone 24 hours a day: from 22:00 Saturday to 22:00 Friday (CET).
• 24-hour consultations with technical support specialists.
• Accounts can be opened in several minutes, with no necessity to compile and send documents. We will prepare the documents and will send you an original of our agreement.
• Flexible and quick replenishing and withdrawing of funds. Bank transfers in euro, US dollars, electronic payments via webmoney, replenishment of funds by credit card. All withdrawals of funds are secured by special technology. Only you can withdraw your funds.
• You can open an account in euro, US dollars, Russian rubles, Swiss francs, and British pounds

Thanks to the latest technical innovations:

• The most common MetaTrader 4 trading platform has been tested by time and by thousands of traders across the world. The system operates via a secure protocol, and hence absolute confidentiality is guaranteed. The advantage of this system is that it enables a user to employ lots of indicators and Mechanical Trading Strategies (MTS) which have been developed by other traders.
• It is possible to trade from a computer, notebook, PDA or smartphone.
• With the help of the MultiTerminal software you will be able to manage all your or investor accounts together.

Additional advantages:

• If you have an interval in trading, or if you have funds lying on your account that are not being used for positions, such funds will not remain idle but will yield an additional 2% per annum.
• We are not a tax agent and do not deduct taxes from our customers
• It is possible to earn money on both a price rise and a fall

© Fibo Group Ltd. http://www.fibogroup.com

Roche reports further accelerated sales growth in third quarter

Full-year outlook raised, new Group management team appointed

• Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in Swiss francs); both divisions grow significantly faster than their respective markets¹
• Genentech integration progressing successfully
• New Group leadership appointed

* LC= local currencies
See appendix to this media release for details of quarterly sales growth

Full-year outlook raised

• Roche now expects at least high single-digit full-year sales growth for Pharmaceuticals Division; full-year 2009 sales in both divisions expected to grow well ahead of market
• Roche confirms target of double-digit Core EPS growth in 2009 and 2010 (at constant exchange rates)

Pharmaceuticals Division sustains growth at twice the market average

• Pharma sales grow 12% (11% in Swiss francs) driven by continued strong performance of leading anticancer medicines, Lucentis, Pegasys and Mircera
• Strong demand for Tamiflu continues in third quarter: full-year sales expectation raised from 2.0 to around 2.7 billion francs in 2009 and from 400 million to about 700 million francs in 2010
• MabThera receives EU approval for the treatment of relapsed or refractory chronic lymphocytic leukemia
• Avastin receives US FDA approval for kidney cancer and broader EU approval for breast cancer
• Positive market response to ongoing rollout of RoActemra in EU, market penetration of Actemra in Japan progressing well

Diagnostics Division significantly outperforms the market

• Divisional sales grow 8% (4% in Swiss francs) — more than twice as fast as the global IVD market — driven by all Business Areas, especially Professional Diagnostics
• cobas 8000 modular analyser series receives CE Mark certification for high-throughput clinical chemistry and immunoassay testing

Commenting on the Group’s nine-month sales figures, Roche CEO Severin Schwan said: ‘The Roche Group continued to perform very strongly in the third quarter. Sales by both the Pharmaceuticals and Diagnostics divisions are significantly outgrowing their respective markets. Based on this performance, we expect another very good full-year result. I’m particularly pleased with the excellent progress we’re making in joining forces with Genentech. The new leadership structure we announced recently will ensure that we continue to translate excellent science into innovative medicines for patients.’

Roche Group

Strong sales growth in third quarter

The Roche Group recorded sustained strong sales growth in the first nine months of 2009. Group sales grew 11% in local currencies (9% in Swiss francs; 4% in US dollars) to 36.4 billion Swiss francs. The Pharmaceuticals Division’s sales increased 12% in local currencies (11% in Swiss francs; 6% in US dollars) to 29.0 billion Swiss francs, maintaining growth at twice the global market rate. The Diagnostics Division also continued to outpace market growth, with sales up 8% in local currencies (4% in Swiss francs; -1% in US dollars) to 7.4 billion Swiss francs.

Genentech integration on track, new leadership structure announced

Following the merger agreement with Genentech in March of this year and the rapid completion of the transaction, integration activities have been proceeding successfully and are already yielding substantial productivity gains. The integration will be largely complete by the end of the year. As announced in September, from January 2010 a newly structured Corporate Executive Committee will continue to implement Roche’s focused strategy built around the combination of pharmaceuticals and diagnostics. The broader leadership structure will ensure a diversity of approaches and help drive innovation in the key areas of research and early development. In addition, the integration of Genentech and Roche will enhance the Group’s innovative capabilities by facilitating knowledge transfer within the Group. Combining the two companies’ late-stage product development, manufacturing and commercial operations will enable the Roche Group to leverage its global scale, as well as achieving efficiencies.

Outlook

Based on the sales results of the nine months, Roche has raised its full-year outlook for 2009. The Group now expects full-year sales in both divisions to grow well ahead of the market, with at least high single-digit sales growth for the Pharmaceuticals Division. The Group is aiming for double-digit Core EPS growth in both 2009 and 2010 (at constant exchange rates). Given the rapid progress in integrating Genentech, Roche expects to see further productivity gains next year. By 2011 the Group aims to achieve pre-tax annual synergies of approximately 1 billion Swiss francs. Based on the strong operating free cash flow, Roche expects to reduce debt progressively and to return to a net cash position by 2015 while maintaining its dividend outlook.

Pharmaceuticals Division

Sales continue to grow at twice the global market rate

*Rest of World
**Local growth rates versus YTD September 2008

Sales by the Pharmaceuticals Division in the first nine months rose 12% in local currencies (11% in Swiss francs, 6% in US dollars) to 29.0 billion Swiss francs, or double the global pharmaceuticals market growth rate (6%)². Excluding Tamiflu, the division’s sales increased 6%, in line with global market growth, driven by strong demand for Avastin, Herceptin, MabThera/Rituxan, Lucentis, Pegasys and Mircera. The worldwide spread of the pandemic A (H1N1) 2009 influenza virus led to exceptionally strong demand for Tamiflu in the second and third quarters.

The division recorded above-market sales increases in all regions, led by Japan and Europe/Rest of World³ (RoW). Solid growth of Avastin, Lucentis and other key products, together with strong growth of Tamiflu, more than offset lower sales of CellCept and Boniva in the United States and the impact of the voluntary withdrawal of Raptiva from the US market in 2009. Sales by Chugai in Japan increased strongly due to demand for Tamiflu, Avastin, Herceptin and Actemra. Sales in Europe/RoW were driven by demand for Tamiflu, Avastin, Herceptin and MabThera/Rituxan.

Global sales of the antiinfluenza medicine Tamiflu (oseltamivir) totalled 2.0 billion Swiss francs in the first nine months, an increase of 362%, or 1,576  million francs, over the same period last year. This exceptional growth was driven by substantially increased demand in the second and third quarters from governments and in the retail pharmacy sector during the current pandemic A (H1N1) 2009 influenza virus (‘swine flu’) outbreak. Sales for pandemic stockpiling amounted to 1,380 million francs in the first nine months. Sales of Tamiflu in the third quarter totalled 994 million francs, compared with 101 million francs in the third quarter of 2008. Based on current estimates, Roche expects full-year sales of Tamiflu of around 2.7 billion francs in 2009 and about 700 million francs in 2010. This is, however, difficult to predict and will depend on levels of infection due to the pandemic A (H1N1) virus and seasonal influenza strains in the coming northern hemisphere winter, as well as government orders in the fourth quarter. Roche is working with the World Health Organization and governments worldwide to support pandemic preparedness and supply Tamiflu to patients in need.

The Roche Group’s key cancer medications continued to show solid growth through the third quarter. Nine-month sales of Avastin (bevacizumab), for advanced colorectal, breast, lung and kidney cancer, and for relapsed glioblastoma (a type of brain tumour), rose 26% to 4.7 billion Swiss francs. Sustained growth in all regions was driven primarily by continued uptake in colorectal, breast and lung cancer. Uptake in Japan, where Avastin is currently approved for advanced colorectal cancer, remains particularly strong. Rollout of Avastin in the United States in the recently approved indications relapsed glioblastoma and advanced renal cell carcinoma is progressing according to plan. Herceptin (trastuzumab), for HER2-positive breast cancer, is experiencing particularly strong growth in Japan and emerging markets. Sales in the first nine months advanced 9% to 4.0 billion Swiss francs. Overall sales (oncology and autoimmune diseases) of MabThera/Rituxan (rituximab), for non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL) and rheumatoid arthritis (RA), rose 8% to 4.6 billion Swiss francs. Growth in the oncology segment is being driven by uptake in CLL following approval in the EU earlier in the year. Sales in the RA segment are being driven mainly by increasing use of MabThera/Rituxan in patients with an inadequate response to a single tumour necrosis factor (TNF) inhibitor in the EU and multiple TNF inhibitors in the US. Sales of Xeloda (capecitabine) and Tarceva (erlotinib) increased 11% and 10%, respectively, to 952 million and 962 million Swiss francs. Sales of Xeloda, for colorectal, stomach and breast cancer, were driven primarily by strong gains in the United States, Japan and China. Sales of Tarceva, for advanced lung and pancreatic cancer, were driven by strong growth in Western Europe and Japan, with additional contributions from CEMAI ⁴ and Asia–Pacific countries.

US sales of Lucentis (ranibizumab), for wet age-related macular degeneration (AMD), increased 21% to 869 million Swiss francs compared with the prior-year period. Solid growth was driven primarily by an increase in the number of Lucentis injections administered to patients in the first and second year of treatment, growth in the number of patients treated for wet AMD and continued improvement in market conditions compared with the first nine months of 2008.

Sales of Pegasys (peginterferon alfa-2a), for hepatitis B and C, rose 11% to 1.3 billion Swiss francs. Growth was driven by continued demand in emerging markets and market-share gains worldwide.

In a highly competitive, price-sensitive market, sales of the renal anemia medication Mircera (methoxy polyethylene glycol-epoetin beta), which is now available in more than 80 countries worldwide, rose 296% to 123 million Swiss francs in the first nine months. Growth is being driven primarily by the success of the product in the predialysis segment. Combined sales of the Group’s established anemia medicines, Roche’s NeoRecormon and Chugai’s Epogin (epoetin beta), declined 9% to 1.2 billion Swiss francs. The decline in NeoRecormon sales of 12% was due mainly to price erosion. The more moderate reduction in sales of Epogin in Japan (-2%) reflects stabilisation of the product’s market share despite continued strong competition.

Sales of CellCept (mycophenolate mofetil), for the prevention of solid organ transplant rejection, decreased 14% compared with the year-earlier period to 1.3 billion Swiss francs. As expected, in the second and third quarters sales fell sharply year-on-year as a result of the expiry of the product’s US patent in May. The erosion of US sales through generic competition was partly offset by continued solid growth elsewhere, especially in Latin America and China.

Sales uptake of the novel rheumatoid arthritis (RA) medicine RoActemra (tocilizumab, known as Actemra outside Europe) in its initial European launch markets has been strong, and the response from physicians is very encouraging. Actemra/RoActemra is now available in eight EU countries, including Germany, as well as Switzerland, India, Brazil and several other countries worldwide. RoActemra is scheduled for launch in additional key EU markets by the end of the year. In Japan, where Actemra was approved for RA in adults and for related pediatric indications in April 2008, market penetration is progressing well.

Product development highlights

In the third quarter of 2009 the Pharmaceuticals Division gained a number of major regulatory approvals and filed important new marketing applications. In July the EU authorities approved the use of Avastin in combination with docetaxel, a commonly used chemotherapy, in the first-line treatment of metastatic breast cancer. The expanded indication, which follows EU approval for combined Avastin and paclitaxel in 2007, means that more patients can benefit from Avastin-based treatment options. In August the US Food and Drug Administration (FDA) approved Avastin in combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma, the most common type of kidney cancer. In September Roche received EU approval for the use of MabThera in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), the most common form of the disease in adults. In July the FDA designated for priority review two supplemental Biologics License Applications (sBLAs) submitted by Genentech and Biogen Idec, for approval of Rituxan plus standard chemotherapy in previously untreated or treated CLL. In September Chugai received approval in Japan for additional indications for Xeloda and Avastin. Xeloda can now be used in combination with oxaliplatin chemotherapy, with or without Avastin, in the first- or second-line treatment of patients with metastatic colorectal cancer.

In July the FDA accepted Roche’s resubmission for its US marketing application for Actemra for rheumatoid arthritis. This follows the FDA’s complete response in September 2008 and subsequent discussions with Roche. The FDA has designated a six-month review timeline for the resubmission. Also in July, Chugai filed a marketing application with the Japanese authorities for approval of Mircera (currently known in Japan by its project code, RG744) for renal anemia. In September Roche filed an application with the EU’s European Medicines Agency to expand the marketing authorisation for RoActemra to include inhibition of the progression of joint damage and improvement of physical function in patients with rheumatoid arthritis. The filing follows positive two-year data from the phase III LITHE trial.

Also in September Roche submitted an application to the EU health authorities to expand approval for Herceptin to include treatment of advanced HER2-positive stomach cancer. The filing is based on the results of the international phase III ToGA trial. In mid-September Chugai filed a marketing application in Japan for approval of Tarceva in the additional indication of pancreatic cancer.

So far this year the division has reported positive results from nine major phase III clinical trials with the potential to significantly expand the use of key products. In July the Group announced the results of two phase III studies, BRAVO and CRUISE, which showed that Lucentis improved vision in patients with swelling in the retina (macular edema) due to branch retinal vein and central retinal vein occlusion, respectively. The data will be used to support a planned supplemental Biologics License Application to the US FDA for Lucentis in retinal vein occlusion.

In September Roche, Genentech and Biogen Idec announced results from an international phase III study (PRIMA), showing that MabThera/Rituxan maintenance therapy can significantly increase the time until the disease progresses in newly-treated patients with advanced follicular lymphoma, a common type of non-Hodgkin’s lymphoma. Because PRIMA met its endpoint during a pre-planned interim analysis, the study was stopped early on the recommendation of an independent data and safety monitoring board. Data from the trial will be filed with EU and US health authorities to extend the current label for MabThera/Rituxan.

In addition, two new studies published in September reported increased survival rates in patients with avian flu (H5N1) and severe seasonal flu who were treated with Tamiflu: in the first of these observational studies 53% of patients with H5N1 infection survived when treated with Tamiflu, compared with 12% of untreated patients; the second trial showed that the death rate was reduced by 37% in high-risk patients with severe seasonal flu who received Tamiflu, compared with no treatment.

R&D pipeline

As of 30 September 2009 the Pharmaceuticals Division’s research and development pipeline (phase I to III/registration) included 63 new molecular entities and 61 additional indications. In the third quarter of 2009 four projects entered phase II development. Portfolio prioritisations led to the discontinuation of one phase I and one phase II project.

Diagnostics Division

Sales continue to grow significantly faster than the market

In the first nine months of 2009 sales by Roche’s Diagnostics Division, the leader in in vitro diagnostics (IVDs), increased 8% in local currencies (4% in Swiss francs, -1% in US dollars) to 7.4 billion Swiss francs. This was more than twice global IVD market growth, which is estimated at 3%.⁵ All five business areas helped drive growth, with Professional Diagnostics again making the biggest contribution. Divisional sales grew ahead of the market in all regions except Japan, where price cuts led to a slight decline in sales. Nine-month sales in the emerging seven (E7) markets (Brazil, Russia, India, China, Korea, Mexico and Turkey) grew 25% and accounted for over 10% of divisional sales.

Roche Professional Diagnostics’ nine-month sales grew roughly twice as fast as the market, rising 9% to 3,363 million Swiss francs. The immunoassay business gained additional market share on sales growth of 19%, driven by new placements of cobas analysers and strong sales of assays for cardiac markers and hepatitis C virus. Coagulation monitoring sales increased 24%, strengthening Roche’s leadership in this segment. Clinical chemistry sales rose 5%, in line with growth in this more mature market. The cobas 8000 modular analyser series for high-throughput laboratories — the largest laboratory customer segment by sales — received CE Mark certification in August. The rollout of this new flagship serum work area platform commenced with the high-speed c701 clinical chemistry module, now available in several configurations in the EU and other markets recognising CE Marking. Four cobas 8000 clinical chemistry and immunoassay modules will be available worldwide in a total of 38 configurations by the end of 2010.

Roche Diabetes Care’s sales rose 4% to 2,158 million Swiss francs. Sales of blood glucose (BG) monitoring systems continued to show single-digit growth (4%) despite the economic downturn. Accu-Chek Aviva and Accu-Chek Performa remained the primary growth drivers, with the new Accu-Chek Aviva Nano and Mobile monitoring systems introduced earlier this year also contributing to sales. Insulin delivery systems contributed positively to growth, helped by strong uptake of the new Accu-Chek Combo interactive insulin pump/BG meter combination, which was launched in an additional five European markets in the third quarter. Promising preliminary results from the Accu-Chek 360° View Outcome study were presented at the recent European Diabetes Congress. They suggest that structured BG testing can contribute to a better understanding of metabolic fluctuations and improved glycemic control in type 2 diabetes.

Roche Molecular Diagnostics’ sales rose 5% to 882 million Swiss francs. Blood screening remained the primary growth driver, with sales up 8% for the period. The unit maintained its leadership in virology with 4% sales growth, slightly below anticipated market growth. In September Molecular Diagnostics launched the new, fully automated cobas 4800 platform with tests for Chlamydia trachomatis and Neisseria gonorrhoeae in Australia and New Zealand. Further launches, with an expanded test menu including a new human papillomavirus screening test that can simultaneously identify high-risk genotypes 16 and 18, are planned for the fourth quarter in Europe and other markets that accept CE Mark certification.

Roche Applied Science’s sales totalled 616 million Swiss francs, an above-market increase of 12% over the year-earlier period. The MagNA Pure and LightCycler systems (nucleic acid purification and PCR analysis) were again the biggest contributors to growth (24%), helped by strong demand for instruments and reagents for pandemic influenza testing and surveillance. The RealTime ready Influenza A/H1N1 test, launched for research use in May, just weeks after the new virus was detected, has generated very strong sales; a filing for approval for clinical use in emergency situations was submitted to the US Food and Drug Administration in September. Sales of DNA sequencing systems were up 12% despite a decline in research funding, notably in the US. In September Applied Science launched MagNA Pure 96, a fully automated high-throughput nucleic acid purification system tailored to the needs of the pharmaceutical industry and academic researchers.

Roche Tissue Diagnostics’ sales totalled 346 million Swiss francs, a 30% increase over the eight months’ sales consolidated in the year-earlier period following the Ventana acquisition in February 2008. On a comparable basis, sales rose 20%, significantly outpacing the market. Advanced tissue staining remained the primary growth driver, with immunohistochemistry reagents and advanced staining instruments like the BenchMark Ultra fuelling robust 29% growth in this segment. In the high-volume primary staining market sales were up 47%, driven by instruments and reagents for hematoxylin/eosin staining. In September the business area launched its INFORM MET DNA Probe, a CE-marked probe to detect genomic gain (extra copies) of the MET gene in non-small cell lung cancer and gastric cancer.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80’000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

1) Unless otherwise stated, all growth rates are in local currencies Barring unforeseen events.
2) Pharmaceutical market growth according to IMS (to end of June 2009)
3) Roche defines Europe/Rest of World as covering Europe and all other countries except Japan and the United States
4) CEMAI: Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent
5) Estimated IVD market growth rates based on company estimates and various industry reports.

Disclaimer: Cautionary statement regarding forward-looking statements
This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

I want a place where I belong
I want a face that makes me strong and
I know quite well that
I’ll have it all
I’ll have it all today
Have it all today

I want some lemonade today
Want someone to go my way
I want a girl that loves me so
And I want you to sing no, no
I’m just like anybody else
I’m just the same like you
Want you tonight and every day
Want you to go my way

I’ll have it all today…..

Ringtones to your

President Dmitry Medvedev blasted Russia’s lack of a leading ‘e-government’ computer infrastructure Monday, saying “the situation is unacceptable.”

“The state computerization expenses are absolutely comparable to the expenses of European countries,” Medvedev said at a meeting on the modernization of the Russian economy. “[Comparing] Russia and Germany, we spend about the same percentage of the GDP, but the effectiveness of this spending is very low,” he added.

Leading by example, the Kremlin launched a new website and YouTube channel today, coinciding with the nationwide Sept. 1 back to school day. The video leading the new channel is an address from Medvedev to students, one of just four videos on the page so far but the Kremlin plans to continually update the Web site with Medvedev’s direct addresses to the country as well as snippets of his speeches.

 Turkey Real Estate has been booming in recent years, helped by a fast-growing population and a seven per cent growth in GDP every year since 2001. The Bank of America says that Turkish property offers a `safe haven` during these difficult times. Last year, nine million tourists descended on Antalya to make the most of a 35-mile stretch of beach that includes the classical site of Side and Belek, a burgeoning upper class family beach & golf resort. Antalya, a place that has hosted 7 civilizations with over 10,000 year old historical sites, has been transformed into a cosmopolitan city of about 700,000, a fascinating old town, with ancient ramparts dating from Roman times and a pretty port, all of which are a big draw for the tourists. Retired policemen Andrew Perry and Bob Cotgrove, both 52, were quick to see the opportunity of buying in the area four years ago.

Bob and his wife Nicky bought a two-bedroom villa with garden and shared swimming pool on a new development five minutes from the beach for Ј40,000, and Andrew, who lives in Leeds when he`s not in Turkey, quickly followed. Sensing that the area was about to take off - their villas are now worth Ј75,000 each - the pair joined Turkish Property World to sell Antalya to British buyers. `Britons were very slow to appreciate this area, whereas the Scandinavians have been buying here for years. Demand is increasing every year,` says Carol, of Turkish Propwerty World, Antalya who has sold 25 properties to Britons in the past year and more to buyers in mainland Europe. `The great golf courses, cultural history, fantastic beaches and, of course, the prices, have been a big draw.` Nor is it all new-build. There is a maturing resale market, as Phil Rodda, 47, a trainer in child protection, and his wife Lorraine, 53, a dental hygienist, discovered. They have bought a ten-year-old two-bedroom top-floor apartment in a three-storey block on the Green Apart apartments in Belek.

 They paid Ј40,000 in November and intend to use it as a holiday home, while also renting it out to family and friends. `We were looking in Spain, but were put off by all the problems there and oversupply. We`d been to Turkey before and liked it and were amazed at the prices,` says Phil who lives near Hebden Bridge, West Yorkshire, and flies to Antalya from Manchester. Phil, who paid just Ј2,000 in fees, adds: `The flat has two balconies and used to be part of a hotel that has now been beautifully refurbished as individual flats around a central pool.` A four-bedroom duplex apartment in Kemer, an ancient Greek city with ruins on the beach, can be bought for Ј100,000 and a smaller villa for Ј80,000. `Prices at the low end are rising in line with inflation,` says Cotgrove, `although in some of the most sought-after areas around marinas it`s more like 15 to 20 per cent.` Taxes and solicitors` fees work out at three per cent of the purchase price, and Turkish bank accounts pay interest of between 12 and 14 per cent. `It helps that the pound has been relatively strong against the Turkish lira,` says Cotgrove, who rents out his villa for Ј300 a week in high season. He lets only to family and friends, but says he could easily rent it out for at least three months a year, which would give him a ten per cent return on his investment.

The Association of British Travel Agents said that Turkey overtook Spain last year as the most popular overseas destination for UK tourists, and overall tourism has risen 14 per cent to 24 million visitors, according to the Turkish Tourist Office. With the continued strength of the euro, numbers from the UK are likely to go up again this year.`Antalya is the same flight time from the UK as Tenerife, but property is about a quarter of the price,` says Cotgrove. `It really is boom time here.`

Now, a new mineral make-up brand has gone a step farther and developed what may be a truly revolutionary approach in cosmetics - and one that seems to be paying off in a big way.

The company, RAW Minerals, was the brainchild of cosmetic scientist Christina Maraccini, and is the first high-performance mineral makeup based on all-natural ingredients designed to actually improve skin health. But their goal wasn’t just to let women consolidate their cosmetics and anti-aging routine into one; they were also determined to change the way that woman sampled and purchased cosmetics.

All mineral make-ups are not the same

Raw Minerals starts by producing a marvelous make-up. According to Christina, “We searched all over the world to find the most innovative botanical extracts and infuse them into lighter-than-air powders that veil the skin in beautiful color and leave skin radiantly healthy and soft to the touch. It gives you a light, natural, long-lasting glow that simply can’t be duplicated by other types of makeup.”

A make-up that can actually improve skin health and reduce the appearance of wrinkles

Next, Christina wanted to deliver powerful anti-aging and anti-wrinkle effects. So she formulated RAW Minerals to include natural botanicals that instantly fill facial lines to reduce the appearance of wrinkles, absorb and help control the effects of skin oil and visibly smooth and refine skin texture. Because RAW Minerals is non-comedongenic, it won’t clog pores and will not aggravate an acne condition or cause a flare-up as easily as traditional make-up.

No department stores, so no department store prices

As an industry veteran, Christina also understood the huge amounts spent by cosmetic brands to market their products. She wanted to avoid these expenses so that she could afford to use the best ingredients regardless of cost, while still delivering a great value to her customer. So, in a risky move, she decided to forego department store distribution and make RAW Minerals available only through the company’s web site on a direct-to-consumer basis.

Try it before you buy it

It’s one thing to brush on a little make-up on at the cosmetic counter to see if you like it, but Christina wanted to let women really have a chance to use her product before they decided to buy it. So she developed a Free Trial whereby customers are sent a complete kit, containing everything needed to achieve a flawless, glowing complexion. Customers are given 30 days to use the products as much as they want and really get a feel for it before they decide if they want to buy.

Clearly, the company’s strategy is a hit with consumers as sales of this innovative new make-up have been phenomenal.

To learn more about RAW Minerals and their free trial offer - click here.

Love is love wherever you live. Because this is feeling and of course we can tell about Love, show it and do some things, but the feeling of love is the bases for this. So, love is first, deeds – second. And it is easier to find your love when you say to yourself: “I love because I like to love!” But Love is only a feeling and relations are work. You know that lift can ride up or down and when this lift stays it means that no one use it. The same we can say about relations. Relations are like the work of art. And this is great to be its author. But it is difficult to do this when you are alone. Do you agree? We need to find our better half. And how can we do this? How can we feel whether this is the right person for us or not? What is this? Intuition? Mind? Or we somehow feel this with our heart?

There are a lot of interesting theories about this. Some people say that man with black hair mostly prefer blond ladies and vice versa. But how to be with those whose hair is hard to identify, or with ladies who colored their hair? Others believe that everything depends on the character and say that extremes always meet. But don’t you know such couples where both are calm, or both are very active? I know. Then, what should we do? How to solve this problem? You can read a lot of pieces of advice or simply do like you wish. But it is well known that there cannot be a universal pattern. Maybe that’s a pity, but don’t you think that if we knew everything from the very beginning it would be pretty boring to live?

So, try everything and communicate with a lot of people and then, you will really find your true love and build strong relations. But if you believe in a scientific approach, then, you can check how compatible you are to your lady on the Love Calculator and find out how many percents of love are between you!

* * *

And in the conclusion I just want to add that love is not about finding the right person, but creating right relationships!

Cheers! See you later!

RUSSIAN BRIDES

Reporting from Moscow — President Obama and his family arrived in Russia early this morning, stepping off Air Force One under a gray sky ahead of a day of meetings at the Kremlin.

After a visit to the Tomb of the Unknown Soldier, Obama met with Russian President Dmitry Medvedev in the Kremlin.

Medvedev said he expects that, in their talks, the two will be closing some debates of the past and opening some debates of the future.

Obama said he thinks the Russians and Americans "have more in common than they have differences." The two shook hands and smiled for photographers.

Even before the president arrived for the round of nuclear-arms talks, administration officials were already predicting the two leaders would announce tentative agreements as early as today.

They also may announce formally a deal with the Russians to allow the Americans use of their airspace to travel to and from Afghanistan.

The ultimate goal is to replace the START arms-reduction treaty, which expires at the end of this year. And there are still significant obstacles to that.

Speaking with Russian television over the weekend, Obama said only that he hoped to get the "framework" of a treaty together during his meetings with Medvedev.

"For us to send a strong signal that we want to reduce our stockpiles, I think, would help us internationally, to give people a sense that we’re moving into a new era and we want to get beyond the Cold War," Obama said in an interview with ITAR-TASS TV.

Gary Samore, the White House pointman on weapons of mass destruction, acknowledged that a major point of contention is the U.S. push for a missile defense system based in Poland and the Czech Republic.

Russian officials consider that a direct challenge to their nuclear program — and a stumbling block to the "New Start" agreement.

The president, First Lady Michelle Obama and their two daughters met a small greeting party at the airport.

As they made their way from the airport into the city of Moscow, the streets were intermittently lined with people watching the motorcade pass. A few waved the "peace" sign, but mostly they just looked on silently.

At the Tomb of the Unknown Soldier, a military band played a mournful tune as a military escort accompanied President Obama and the first lady in a slow procession to a bowl with a flickering flame. The soldiers placed a wreath before the flame, and Obama adjusted it a little before the band struck up the U.S. national anthem.

On Sunday, there would be a private memorial for the Jackson family and relatives.

Jackson’s body might be buried at his Neverland Ranch. Sources quoted his mother, Katherine Jackson, talking about the initial plans for Jackson’s funeral.

Neverland Ranch.

Michael Jackson Neverland RanchMichael Jackson Neverland Ranch